-
2024 CUDA丨Dr. Guohua Zeng: China’s Leading Role in Minimally Invasive Urological Stone Surgery, Enhancing Patient Quality of Life
The 2024 Annual Meeting of the Urological Surgeons Branch of the Chinese Medical Association (CUDA) was held in Xi’an from August 8 to 11, 2024. The conference, organized by the Chinese Medical Association and the CUDA Urological Surgeons Branch, was hosted by the Air Force Medical University Xijing Hospital and co-organized by the Shaanxi Provincial…
-
Dr. Hailiang Zhang: Analyzing the Characteristics of Chinese UTUC Patients and Exploring Targeted Treatment Strategies to Meet the Needs of More UTUC
Upper tract urothelial carcinoma (UTUC), which includes renal pelvis cancer and ureteral cancer, is classified alongside bladder cancer as a type of urothelial carcinoma. However, the overall incidence of UTUC is relatively low, and there are still some contentious issues in its diagnosis and treatment strategies. At the recent 2024 Annual Meeting of the Urological…
-
2024 CUDA丨Dr. Tie Zhong: New Endocrine Therapies Improve Prognosis in mHSPC, Optimizing Precision Treatment Through Stratified Approaches
The 2024 Annual Meeting of the Urological Surgeons Branch of the Chinese Medical Association (CUDA) was held in Xi’an from August 8 to 11, 2024. The conference was hosted by the Chinese Medical Association and the CUDA Urological Surgeons Branch, with the Air Force Medical University Xijing Hospital serving as the organizer and the Shaanxi…
-
2024 CUDA丨Dr. Jian Huang: Exploring the Potential Benefits of Robot-Assisted Function-Preserving Radical Cystectomy for Bladder Cancer Patients
Robot-assisted radical cystectomy is playing an increasingly significant role in the treatment of bladder cancer. At the 2024 Annual Meeting of the Urological Surgeons Branch of the Chinese Medical Association (CUDA) held in Xi’an from August 8 to 11, Dr. Jian Huang from Sun Yat-sen Memorial Hospital, Sun Yat-sen University, shared his insights on “Robot-Assisted…
-
2024 CUDA丨Dr. Wei Yu: Optimal ADC Strategies in the Systemic Treatment of Urothelial Carcinoma
Urothelial carcinoma (UC) is one of the most common malignancies in the urinary system. With the increasing availability of ADC (antibody-drug conjugate) drugs in clinical practice, optimizing ADC drug selection and combination therapies, as well as managing treatment-related adverse events, have become critical issues. Following the successful 2024 Annual Meeting of the Urological Surgeons Branch…
-
2024 CUDA丨Dr. Xiangjun Lyu: Addressing Incontinence Early, Enhancing Pelvic Floor Disease Outcomes with Robotic Surgery
The 2024 Annual Meeting of the Urological Surgeons Branch of the Chinese Medical Association (CUDA) was held in Xi’an from August 8 to 11, 2024. The conference was hosted by the Chinese Medical Association and the CUDA Urological Surgeons Branch, with the Air Force Medical University Xijing Hospital serving as the organizer and the Shaanxi…
-
The First Mid-Term Milestone of the End TB Strategy: Global Progress and Key Findings
Editor’s Note: Tuberculosis (TB) remains a significant public health challenge worldwide, particularly in economically underdeveloped regions. Although progress has been made in TB diagnosis and treatment in recent years, factors…
-
Are OTC Eye Drops Safe? CRPA Outbreaks in Multiple U.S. States Trace Back to Artificial Tears
Editor’s Note: Artificial tears are substitutes that mimic the composition of natural tears, providing lubrication to the eyes and alleviating symptoms of dry eye, such as pain and burning. However,…
Connecting Medical Expertise through Media